The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability
- 1 March 2004
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 95 (3) , 447-453
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Engineering of Dendrimer Surfaces to Enhance Transepithelial Transport and Reduce CytotoxicityPharmaceutical Research, 2003
- The influence of surface modification on the cytotoxicity of PAMAM dendrimersInternational Journal of Pharmaceutics, 2003
- Role of P-Glycoprotein in PharmacokineticsClinical Pharmacokinetics, 2003
- Drug–drug interaction mediated by inhibition and induction of P-glycoproteinAdvanced Drug Delivery Reviews, 2003
- Polyamidoamine Starburst® dendrimers as solubility enhancersInternational Journal of Pharmaceutics, 2000
- P-glycoprotein mediated multidrug resistance and its implications for pathologyPathology, 1997
- Dendrimer MoleculesScientific American, 1995
- Biocatalytic resolution of DL-propranolol. A successful example of computer-aided substrate designTetrahedron, 1993
- Epithelial Transport Of Drugs In Cell Culture. I: A Model For Studying The Passive Diffusion Of Drugs Over Intestinal Absorbtive (Caco-2) CellsJournal of Pharmaceutical Sciences, 1990
- Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assaysJournal of Immunological Methods, 1983